

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT ENTERING INTO EXCLUSIVE LICENSE AGREEMENT FOR SYH2086 WITH MADRIGAL**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has entered into an exclusive license agreement (the “**Agreement**”) with Madrigal Pharmaceuticals, Inc. (“**Madrigal**”) for the global development, manufacturing and commercialization of the Group’s oral small molecule glucagon-like peptide-1 (“**GLP-1**”) receptor agonist, SYH2086.

Under the terms of the Agreement, the Group agreed to grant Madrigal an exclusive license to develop, manufacture and commercialize SYH2086 worldwide, while retaining the Group’s right to develop and commercialize other orally administered small-molecule GLP-1 receptor agonist products in China. The Group is eligible to receive a total consideration of up to US\$2.075 billion, including an upfront payment of US\$120 million plus potential development, regulatory, and commercial milestone payments of up to US\$1.955 billion, and up to double-digit royalties based on the annual net sales of SYH2086.

#### **About SYH2086**

SYH2086, a preclinical candidate developed by the Group with complete intellectual property rights, is a novel oral small molecule GLP-1 receptor agonist. GLP-1 receptor agonists are a class of drugs that exert their effects through the GLP-1 receptor and have been developed as treatments for the management of type 2 diabetes and obesity. Their core mechanisms of action include enhancing insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite, thereby offering both glycemic control and weight loss benefits. Preclinical data demonstrated that SYH2086 exhibited excellent in vitro agonistic activity and in vivo glucose-lowering and weight-loss effects, as well as a linear pharmacokinetic (PK) profile over a wide dose range across multiple animal species, with no significant safety risks observed.

## About Madrigal

Madrigal (NASDAQ: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (“**MASH**”), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR- $\beta$  agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by the U.S. Food and Drug Administration for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c). For more information, please visit [www.madrigalpharma.com](http://www.madrigalpharma.com).

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 30 July 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.*